Dimerix Limited (AU:DXB)
ASX:DXB
Want to see AU:DXB full AI Analyst Report?
DXB Stock Chart & Stats
AU$0.40
-AU$0.03(-5.00%)
At close: 4:00 PM EST
AU$0.40
-AU$0.03(-5.00%)
Day’s Range― - ―
52-Week RangeAU$0.20 - AU$0.71
Previous CloseN/A
Volume4.60M
Average Volume (3M)1.47M
Market Cap
AU$129.09M
Enterprise ValueAU$90.63M
Total Cash (Recent Filing)AU$38.49M
Total Debt (Recent Filing)AU$33.42K
Price to Earnings (P/E)―
Beta2.45
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding600,396,800
10 Day Avg. Volume1,720,426
30 Day Avg. Volume1,468,144
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)24.09
Price to Sales (P/S)256.86
P/FCF Ratio8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$18.30M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent high revenue growth (70.03%) indicates expanding commercial traction or milestone-driven topline expansion; over several months this supports sustained R&D funding, validates demand for lead programs like DMX-200, and can improve unit economics as fixed costs are spread with scale.
Balance Sheet HealthAn extremely low debt-to-equity ratio (0.0073) provides material financial flexibility for a biotech in lengthy clinical cycles. Minimal leverage reduces interest burden and insolvency risk, allowing management to prioritize clinical progress and strategic partnerships without heavy debt servicing constraints.
Cash ConversionOperating cash flow converts favorably to reported earnings (ratio 1.76) and FCF aligns closely with net income, showing accounting profits translate into real cash. Reliable cash conversion supports near-term operations and reduces immediate reliance on external funding while clinical programs advance.
Bears Say
ProfitabilityPersistently negative net and EBIT margins (-10.56% and -28.97%) reflect structural unprofitability driven by high operating and development costs. Over a multi-month horizon, sustained losses increase financing needs and suggest the company must materially improve margins or secure recurring revenue to achieve long-term viability.
Return On EquityA severely negative ROE (-99.05%) indicates the company is destroying shareholder value rather than generating returns on invested capital. This structural weakness undermines capital efficiency, complicates future fundraises, and signals management must improve allocation of capital or strategy to restore investor confidence.
Free Cash Flow TrendA dramatic decline in free cash flow growth (-307.61%) shows a worsening cash generation trajectory. Over 2-6 months this raises financing and dilution risk, constrains the ability to progress multiple clinical programs concurrently, and increases reliance on partnerships or equity issuance to fund operations.
Dimerix Limited News
DXB FAQ
What was Dimerix Limited’s price range in the past 12 months?
Dimerix Limited lowest share price was AU$0.20 and its highest was AU$0.71 in the past 12 months.
What is Dimerix Limited’s market cap?
Dimerix Limited’s market cap is AU$129.09M.
When is Dimerix Limited’s upcoming earnings report date?
Dimerix Limited’s upcoming earnings report date is Sep 02, 2026 which is in 115 days.
How were Dimerix Limited’s earnings last quarter?
Dimerix Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.027.
Is Dimerix Limited overvalued?
According to Wall Street analysts Dimerix Limited’s price is currently Overvalued.
Does Dimerix Limited pay dividends?
Dimerix Limited does not currently pay dividends.
What is Dimerix Limited’s EPS estimate?
Dimerix Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dimerix Limited have?
Dimerix Limited has 600,396,800 shares outstanding.
What happened to Dimerix Limited’s price movement after its last earnings report?
Dimerix Limited reported an EPS of -AU$0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.409%.
Which hedge fund is a major shareholder of Dimerix Limited?
Currently, no hedge funds are holding shares in AU:DXB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dimerix Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.10%
12-Months-Change
Fundamentals
Return on Equity
-278.87%
Trailing 12-Months
Asset Growth
194.65%
Trailing 12-Months
Company Description
Dimerix Limited
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease. The company is headquartered in Fitzroy, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Orthocell Ltd
―
Immutep Ltd
―
Race Oncology Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---